TCRT icon

Alaunos Therapeutics

1.96 USD
-0.06
2.97%
At close Dec 20, 4:00 PM EST
1 day
-2.97%
5 days
4.26%
1 month
-7.98%
3 months
-28.99%
6 months
-68.49%
Year to date
-84.63%
1 year
-75.10%
5 years
-99.74%
10 years
-99.73%
 

About: Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.

Employees: 34

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

3.14% less ownership

Funds ownership: 15.15% [Q2] → 12.0% (-3.14%) [Q3]

44% less funds holding

Funds holding: 50 [Q2] → 28 (-22) [Q3]

63% less capital invested

Capital invested by funds: $1.7M [Q2] → $623K (-$1.08M) [Q3]

85% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 26

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 24

Research analyst outlook

We haven’t received any recent analyst ratings for TCRT.

Financial journalist opinion

Charts implemented using Lightweight Charts™